Ike Swetlitz

Amgen Inc. has engaged an independent academic organization to reevaluate data for a rare disease drug that US regulators are trying to pull from the market.

The FDA wants to withdraw approval of Amgen’s drug after years on the market. The company is defending it.

The European Medicines Agency recommended that CSL Ltd.’s drug Tavneos be pulled from the market after finding it was approved based on allegedly incorrect and misleading data, adding pressure to its US manufacturer, Amgen Inc.

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, putting the drug’s continued sales at risk.

Brian Evanko, Cigna Group’s new chief executive officer, said he aims to put patients at the center of the company’s strategy. He’ll have to convince people struggling with rising healthcare costs that he’s serious — and persuade Wall Street that this strategy can be profitable.

Brian Evanko, Cigna Group's new chief executive officer, said he aims to put patients at the center of the company's strategy.

People buying Obamacare health insurance face double-digit premium increases in 2027 for the second year in a row, intensifying the affordability squeeze that has pushed millions to stop signing up for coverage.

People buying Obamacare health insurance face double-digit premium increases in 2027 for the second year in a row, intensifying the affordability squeeze that's led millions to stop signing up for coverage.

Elevance Health Inc. slid in early trading after boosting its profit guidance by less than Wall Street had hoped, as the company grapples with recent federal policy changes that have made healthcare more expensive.

UnitedHealth Group Inc. raised its outlook for the year and reported quarterly profit well ahead of Wall Street’s views, helping to solidify the company’s earnings recovery after a historic collapse.